From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona has a sizable and rapidly growing bioscience industry. State bioscience firms employed 25,686 in 2016 in 1,310 individual business establishments. Industry employment has grown by 9 percent since 2014, twice the growth rate of the nation, with four of the five major subsectors adding jobs during the period. Both drugs and pharmaceuticals and research, testing and medical labs have experienced double-digit job growth since 2014. Arizona inventors have been awarded nearly 2,000 bioscience-related patents since 2014, among the second quintile of states in patent activity. Since 2015, NIH awards to Arizona institutions have increased, reaching $189 million in FY 2017. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
The Arizona Board of Regents and the University of Arizona will be hosting a special event to welcome Ann Weaver Hart to Arizona.
(ARIZONA)—The Arizona Science Center served as the official launching pad for one of the most colorful science extravaganzas Arizona has embarked upon in its nearly 100 year-old history…the first-annual ARIZONA SCITECH festival.
FDA grants Roche’s pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer Media Release: Roche 02 08 2012
PADT Increases Prototyping Capacity with Addition of 3D Systems ProJet HD6000 Stereolithography System